Sihuan Pharmaceutical Sets 26 Aug 2026 Board Meeting to Approve H1 2026 Results and Consider Interim Dividend
Bulletin Express
Aug 14
Sihuan Pharmaceutical Holdings Group Ltd. has scheduled a board meeting for 26 August 2026.
The agenda includes:
1. Reviewing and approving the consolidated interim results for the six months ended 30 June 2026.
2. Authorising publication of the interim financial report.
3. Discussing and, if appropriate, approving the declaration and payment of an interim dividend.
The notice was signed by Chairman and Executive Director Dr. Che Fengsheng on 14 August 2026 in Hong Kong. The board currently comprises five executive directors—Dr. Che Fengsheng, Dr. Guo Weicheng, Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili—and three independent non-executive directors—Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.